opc 12759 has been researched along with Dry Eye Syndromes in 26 studies
rebamipide: structure in first source; RN refers to (+-)-isomer; inhibits gastric xanthine oxidase
Dry Eye Syndromes: Corneal and conjunctival dryness due to deficient tear production, predominantly in menopausal and post-menopausal women. Filamentary keratitis or erosion of the conjunctival and corneal epithelium may be caused by these disorders. Sensation of the presence of a foreign body in the eye and burning of the eyes may occur.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Long-term treatment with topical rebamipide and diquafosol can improve dry eye in patients with cGVHD or OCP-like disease." | 7.81 | Long-term rebamipide and diquafosol in two cases of immune-mediated dry eye. ( Fukui, M; Kamoi, M; Kawakita, T; Mukai, S; Ogawa, Y; Saijo-Ban, Y; Simmura, S; Tsubota, K; Yaguchi, S; Yamane, M, 2015) |
| "The purpose of the study was to compare the two mucin secretogogues, diquafosol (DQS) and rebamipide (RBM), for the treatment of dry eye syndrome (DES) in office workers." | 5.24 | A Prospective, Randomized Trial of Two Mucin Secretogogues for the Treatment of Dry Eye Syndrome in Office Workers. ( Fukagawa, K; Iwasaki, M; Okano, T; Saga, M; Sakata, M; Seika, D; Shimazaki, J, 2017) |
| "In December 2010 and January 2012, 3% diquafosol sodium ophthalmic solution and 2% rebamipide ophthalmic suspension, respectively, appeared first in Japan as prescription drugs for the treatment of dry eye (DE)." | 4.98 | Tear Film-Oriented Diagnosis and Tear Film-Oriented Therapy for Dry Eye Based on Tear Film Dynamics. ( Georgiev, GA; Yokoi, N, 2018) |
| ", uridine triphosphate; UTP), and rebamipide may alleviate human meibomian gland dysfunction (MGD) and/or dry eye disease." | 3.83 | Do Cyclosporine A, an IL-1 Receptor Antagonist, Uridine Triphosphate, Rebamipide, and/or Bimatoprost Regulate Human Meibomian Gland Epithelial Cells? ( Ding, J; Kam, WR; Liu, Y; Sullivan, DA, 2016) |
| "Long-term treatment with topical rebamipide and diquafosol can improve dry eye in patients with cGVHD or OCP-like disease." | 3.81 | Long-term rebamipide and diquafosol in two cases of immune-mediated dry eye. ( Fukui, M; Kamoi, M; Kawakita, T; Mukai, S; Ogawa, Y; Saijo-Ban, Y; Simmura, S; Tsubota, K; Yaguchi, S; Yamane, M, 2015) |
| "The only side effect was dysgeusia (10% patients)." | 3.30 | Efficacy and safety of topical 2% rebamipide ophthalmic suspension in dry eye disease at tertiary care centre. ( Jain, K; Jaju, M; Yadav, D, 2023) |
| "This study enrolled 60 eyes of 30 dry eye patients undergoing corneal refractive surgery." | 2.80 | Effect of Rebamipide Ophthalmic Suspension on Intraocular Light Scattering for Dry Eye After Corneal Refractive Surgery. ( Igarashi, A; Kamiya, K; Kobashi, H; Shimizu, K, 2015) |
| "Because dry eye greatly reduces quality of life, this study aimed to examine rebamipide instillation in patients with dry eye and assess the improvement of signs and symptoms as evaluated with the Ocular Surface Disease Index, which is the most popular index and is highly reliable." | 2.80 | Improvements in Signs and Symptoms of Dry Eye after Instillation of 2% Rebamipide. ( Fujimoto, C; Fujita, M; Igarashi, T; Kobayashi, M; Nakano, Y; Suzuki, H; Takahashi, H; Yamada, Y, 2015) |
| "Secondary subjective end points were dry eye-related ocular symptoms (foreign body sensation, dryness, photophobia, eye pain, and blurred vision) score and the patients' overall treatment impression score." | 2.78 | A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye. ( Awamura, S; Kinoshita, S; Nakamichi, N; Oshiden, K; Suzuki, H; Yokoi, N, 2013) |
| "A randomized, double-masked, multicenter, placebo-controlled, parallel-group, dose-response phase II study." | 2.77 | Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study. ( Awamura, S; Kinoshita, S; Nakamichi, N; Oshiden, K; Suzuki, H; Yokoi, N, 2012) |
| "The etiology of dry eye has not been clarified." | 2.58 | Medical Treatment for Dry Eye in Japan. ( Watanabe, H, 2018) |
| "It has been noted that dry eye in office workers is associated with a decrease in secretory mucin." | 1.51 | The Effects of Rebamipide 2% Ophthalmic Solution Application on Murine Subbasal Corneal Nerves After Environmental Dry Eye Stress. ( Dogru, M; Kojima, T; Nakamura, S; Simsek, C; Tsubota, K, 2019) |
| "Dry eye disease was diagnosed according to: compromised tear dynamics (Schirmer test ≤5 mm or tear break-up time (TBUT) ≤5 sec); ocular surface abnormalities (positive vital staining with fluorescein or lissamine green); and presence of symptoms." | 1.48 | Efficacy of Rebamipide Instillation for Contact Lens Discomfort With Dry Eye. ( Fujimoto, C; Igarashi, T; Kobayashi, M; Suzuki, H; Takahashi, H; Yaguchi, C, 2018) |
| "To determine the mucinogenic effect of dry eye (DE) treatment drugs currently in use, we compared the levels of mucin production and inflammatory cytokine expression on the ocular surfaces using a DE-induced mice model." | 1.48 | Comparison of Ocular Surface Mucin Expression After Topical Ophthalmic Drug Administration in Dry Eye-Induced Mouse Model. ( Ji, YW; Kang, HG; Kim, HC; Lee, HK; Moon, I; Noh, H; Song, JS; Yeo, A, 2018) |
| "The most prevalent subtype of dry eye was aqueous-deficient dry eye, which was present in 35." | 1.46 | A Clinic-based Survey of Clinical Characteristics and Practice Pattern of Dry Eye in Japan. ( Hiratsuka, Y; Kawashima, M; Shigeyasu, C; Suwaki, K; Tsubota, K; Uchino, M; Yamada, M; Yokoi, N, 2017) |
| "Mean dry eye-related symptom score showed a significant improvement from the baseline (14." | 1.42 | Effectiveness and relevant factors of 2% rebamipide ophthalmic suspension treatment in dry eye. ( Maeda, Y; Matsumiya, W; Nagai, T; Nakamura, M; Otsuka, K; Ueda, K, 2015) |
| "A total of 154 patients with dry eye were enrolled in this study." | 1.40 | A multicenter, open-label, 52-week study of 2% rebamipide (OPC-12759) ophthalmic suspension in patients with dry eye. ( Awamura, S; Kinoshita, S; Nakamichi, N; Oshiden, K; Suzuki, H; Yokoi, N, 2014) |
| "A rat model of dry eye was developed by surgical removal of exorbital lacrimal glands." | 1.39 | Protection of human corneal epithelial cells from TNF-α-induced disruption of barrier function by rebamipide. ( Haruta, J; Kimura, K; Morita, Y; Orita, T; Sonoda, KH; Takeji, Y, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 24 (92.31) | 24.3611 |
| 2020's | 2 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Jain, K | 1 |
| Jaju, M | 1 |
| Yadav, D | 1 |
| Eom, Y | 1 |
| Chung, SH | 1 |
| Chung, TY | 1 |
| Kim, JY | 1 |
| Choi, CY | 1 |
| Yoon, KC | 1 |
| Ko, BY | 1 |
| Kim, HK | 1 |
| Kim, MK | 1 |
| Lee, HK | 2 |
| Song, JS | 2 |
| Hyon, JY | 1 |
| Seo, KY | 1 |
| Lee, JS | 1 |
| Kim, HM | 1 |
| Simsek, C | 2 |
| Kojima, T | 3 |
| Nakamura, S | 1 |
| Dogru, M | 3 |
| Tsubota, K | 6 |
| Shamloo, K | 1 |
| Barbarino, A | 1 |
| Alfuraih, S | 1 |
| Sharma, A | 1 |
| Shimazaki, J | 3 |
| Seika, D | 1 |
| Saga, M | 1 |
| Fukagawa, K | 1 |
| Sakata, M | 1 |
| Iwasaki, M | 1 |
| Okano, T | 1 |
| Igarashi, T | 3 |
| Kobayashi, M | 2 |
| Yaguchi, C | 1 |
| Fujimoto, C | 2 |
| Suzuki, H | 5 |
| Takahashi, H | 3 |
| Igarashi, A | 2 |
| Aoki, K | 1 |
| Higa, K | 1 |
| Shimizu, T | 2 |
| Moon, I | 1 |
| Kang, HG | 1 |
| Yeo, A | 1 |
| Noh, H | 1 |
| Kim, HC | 1 |
| Ji, YW | 1 |
| Yokoi, N | 5 |
| Georgiev, GA | 1 |
| Watanabe, H | 1 |
| Hori, Y | 1 |
| Fu, R | 1 |
| Jiang, Y | 1 |
| Zhou, J | 1 |
| Zhang, J | 1 |
| Kimura, K | 1 |
| Morita, Y | 1 |
| Orita, T | 1 |
| Haruta, J | 1 |
| Takeji, Y | 1 |
| Sonoda, KH | 1 |
| Kinoshita, S | 3 |
| Oshiden, K | 3 |
| Awamura, S | 3 |
| Nakamichi, N | 3 |
| Koh, S | 1 |
| Inoue, Y | 1 |
| Sugmimoto, T | 1 |
| Maeda, N | 1 |
| Nishida, K | 1 |
| Ohguchi, T | 1 |
| Ibrahim, OM | 1 |
| Nagata, T | 1 |
| Shirasawa, T | 1 |
| Kawakita, T | 2 |
| Satake, Y | 1 |
| Ishida, S | 1 |
| Kaido, M | 1 |
| Ishida, R | 1 |
| Yamane, M | 1 |
| Ogawa, Y | 1 |
| Fukui, M | 1 |
| Kamoi, M | 1 |
| Saijo-Ban, Y | 1 |
| Yaguchi, S | 1 |
| Mukai, S | 1 |
| Simmura, S | 1 |
| Kamiya, K | 1 |
| Kobashi, H | 1 |
| Shimizu, K | 1 |
| Ueda, K | 1 |
| Matsumiya, W | 1 |
| Otsuka, K | 1 |
| Maeda, Y | 1 |
| Nagai, T | 1 |
| Nakamura, M | 1 |
| Fujita, M | 1 |
| Yamada, Y | 1 |
| Nakano, Y | 1 |
| Akiyama-Fukuda, R | 1 |
| Usui, T | 1 |
| Yoshida, T | 1 |
| Yamagami, S | 1 |
| Kam, WR | 1 |
| Liu, Y | 1 |
| Ding, J | 1 |
| Sullivan, DA | 1 |
| Kawashima, M | 1 |
| Yamada, M | 1 |
| Suwaki, K | 1 |
| Shigeyasu, C | 1 |
| Uchino, M | 1 |
| Hiratsuka, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Late Phase 2 Study of OPC-12759 Ophthalmic Suspension[NCT00475319] | Phase 2 | 308 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
FCS indicates the damage to the corneal epithelium. Per the National Eye Institute/Industry Workshop report, the cornea was divided into 5 fractions, each of which was given a staining score from 0 to 3, and the total score was calculated(0-15). 0 is better.The change from baseline (CFB) to LOCF at the end of instillation (LOCF endpoint) was used to analyze dose-response. A general linear model was used to examine if slope parameters were not equal to zero. (NCT00475319)
Timeframe: Baseline, 4weeks
| Intervention | FCS score (Mean) |
|---|---|
| 1% OPC-12759 Ophthalmic Suspension | -3.5 |
| 2% OPC-12759 Ophthalmic Suspension | -3.7 |
| Placebo | -1.8 |
LGCS indicates the damage to the conjunctival epithelium. Per the National Eye Institute/Industry Workshop report, the conjunctival sac and the conjunctina was divided into 6 ractions, each of which was given a staining score from 0 to 3, and the total score was calculated(0-18). 0 is better. The CFB to each study time point was compared between the active-drug groups and the placebo group, and LOCF endpoint scores were used to compare the active-drug groups and the placebo group. In each treatment group, baseline scores and those obtained at each study time point were compared. (NCT00475319)
Timeframe: Baseline, 4weeks
| Intervention | LGCS score (Mean) |
|---|---|
| 1% OPC-12759 Groups | -4.0 |
| 2% OPC-12759 Groups | -4.5 |
| Placebo | -1.9 |
3 reviews available for opc 12759 and Dry Eye Syndromes
| Article | Year |
|---|---|
Tear Film-Oriented Diagnosis and Tear Film-Oriented Therapy for Dry Eye Based on Tear Film Dynamics.
Topics: Alanine; Antioxidants; Dry Eye Syndromes; Humans; Japan; Mucins; Ophthalmic Solutions; Polyphosphate | 2018 |
Medical Treatment for Dry Eye in Japan.
Topics: Alanine; Dry Eye Syndromes; Humans; Japan; Lubricant Eye Drops; Polyphosphates; Quinolones; Tears; U | 2018 |
Secreted Mucins on the Ocular Surface.
Topics: Alanine; Conjunctiva; Dry Eye Syndromes; Goblet Cells; Humans; Mucin 5AC; Ophthalmic Solutions; Poly | 2018 |
7 trials available for opc 12759 and Dry Eye Syndromes
| Article | Year |
|---|---|
Efficacy and safety of topical 2% rebamipide ophthalmic suspension in dry eye disease at tertiary care centre.
Topics: Case-Control Studies; Dry Eye Syndromes; Fluorescein; Humans; Ophthalmic Solutions; Prospective Stud | 2023 |
Efficacy and safety of 1% and 2% rebamipide clear solution in dry eye disease: a multicenter randomized trial.
Topics: Adult; Alanine; Dry Eye Syndromes; Humans; Middle Aged; Ophthalmic Solutions; Quinolones; Tears | 2023 |
A Prospective, Randomized Trial of Two Mucin Secretogogues for the Treatment of Dry Eye Syndrome in Office Workers.
Topics: Adult; Alanine; Conjunctiva; Dry Eye Syndromes; Female; Humans; Male; Middle Aged; Occupational Dise | 2017 |
A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye.
Topics: Adult; Aged; Alanine; Anti-Ulcer Agents; Coloring Agents; Conjunctiva; Dry Eye Syndromes; Female; Fl | 2013 |
Effect of Rebamipide Ophthalmic Suspension on Intraocular Light Scattering for Dry Eye After Corneal Refractive Surgery.
Topics: Administration, Topical; Adult; Alanine; Anti-Ulcer Agents; Dry Eye Syndromes; Female; Humans; Kerat | 2015 |
Improvements in Signs and Symptoms of Dry Eye after Instillation of 2% Rebamipide.
Topics: Alanine; Dry Eye Syndromes; Female; Humans; Male; Ophthalmic Solutions; Quinolones; Treatment Outcom | 2015 |
Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antioxidants; Coloring Agents; Dose-Response Relationship, | 2012 |
16 other studies available for opc 12759 and Dry Eye Syndromes
| Article | Year |
|---|---|
The Effects of Rebamipide 2% Ophthalmic Solution Application on Murine Subbasal Corneal Nerves After Environmental Dry Eye Stress.
Topics: Alanine; Animals; Anti-Inflammatory Agents; Cornea; Dry Eye Syndromes; Male; Mice; Mice, Inbred BALB | 2019 |
Graft Versus Host Disease-Associated Dry Eye: Role of Ocular Surface Mucins and the Effect of Rebamipide, a Mucin Secretagogue.
Topics: Administration, Ophthalmic; Alanine; Animals; Antioxidants; Bone Marrow Transplantation; CA-125 Anti | 2019 |
Efficacy of Rebamipide Instillation for Contact Lens Discomfort With Dry Eye.
Topics: Adult; Alanine; Antioxidants; Contact Lenses, Hydrophilic; Cytokines; Dry Eye Syndromes; Female; Hum | 2018 |
The Role of 2% Rebamipide Eye Drops Related to Conjunctival Differentiation in Superoxide Dismutase-1 (Sod1) Knockout Mice.
Topics: Alanine; Animals; Antioxidants; Biomarkers; Cell Differentiation; Conjunctiva; Disease Models, Anima | 2018 |
Comparison of Ocular Surface Mucin Expression After Topical Ophthalmic Drug Administration in Dry Eye-Induced Mouse Model.
Topics: Administration, Topical; Alanine; Animals; Anti-Inflammatory Agents; Cyclosporine; Disease Models, A | 2018 |
Rebamipide ophthalmic solution modulates the ratio of T helper cell 17/regulatory T cells in dry eye disease mice.
Topics: Alanine; Animals; Conjunctiva; Cornea; Cytokines; Disease Models, Animal; Dry Eye Syndromes; Female; | 2019 |
Protection of human corneal epithelial cells from TNF-α-induced disruption of barrier function by rebamipide.
Topics: Adherens Junctions; Alanine; Animals; Antioxidants; beta Catenin; Cadherins; Cell Line; Disease Mode | 2013 |
Effect of rebamipide ophthalmic suspension on optical quality in the short break-up time type of dry eye.
Topics: Aberrometry; Adult; Aged; Aged, 80 and over; Alanine; Antioxidants; Corneal Topography; Corneal Wave | 2013 |
The effects of 2% rebamipide ophthalmic solution on the tear functions and ocular surface of the superoxide dismutase-1 (sod1) knockout mice.
Topics: Alanine; Animals; Conjunctiva; Disease Models, Animal; Dose-Response Relationship, Drug; Dry Eye Syn | 2013 |
A multicenter, open-label, 52-week study of 2% rebamipide (OPC-12759) ophthalmic suspension in patients with dry eye.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antioxidants; Cornea; Dry Eye Syndromes; Female; Fluorescei | 2014 |
Short-term effects of instillation of a rebamipide suspension on visual function.
Topics: Adult; Alanine; Dry Eye Syndromes; Female; Humans; Instillation, Drug; Male; Middle Aged; Ophthalmic | 2014 |
Long-term rebamipide and diquafosol in two cases of immune-mediated dry eye.
Topics: Administration, Topical; Aged; Alanine; Drug Therapy, Combination; Dry Eye Syndromes; Enzyme Inhibit | 2015 |
Effectiveness and relevant factors of 2% rebamipide ophthalmic suspension treatment in dry eye.
Topics: Aged; Alanine; Antioxidants; Cornea; Dry Eye Syndromes; Enzyme Inhibitors; Female; Fluorescein; Fluo | 2015 |
Evaluation of Tear Meniscus Dynamics Using Anterior Segment Swept-Source Optical Coherence Tomography After Topical Solution Instillation for Dry Eye.
Topics: Administration, Topical; Adult; Alanine; Anterior Eye Segment; Cross-Sectional Studies; Dry Eye Synd | 2016 |
Do Cyclosporine A, an IL-1 Receptor Antagonist, Uridine Triphosphate, Rebamipide, and/or Bimatoprost Regulate Human Meibomian Gland Epithelial Cells?
Topics: Alanine; Antihypertensive Agents; Antioxidants; Antirheumatic Agents; Bimatoprost; Cell Count; Cell | 2016 |
A Clinic-based Survey of Clinical Characteristics and Practice Pattern of Dry Eye in Japan.
Topics: Aged; Alanine; Cross-Sectional Studies; Diagnostic Techniques, Ophthalmological; Dry Eye Syndromes; | 2017 |